Form 4: Apogee Therapeutics CMO Executes Stock Option Plan

Chief Medical Officer Carl Dambkowski exercised options and sold 5,500 shares of Apogee Therapeutics common stock.

Summary

• Chief Medical Officer Carl Dambkowski exercised options for 4,125 shares at a price of $22.86 per share.
• Following the exercise, the reporting person sold a total of 5,500 shares in two separate transactions.
• The sales were executed at weighted average prices of $83.92 and $84.60 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
• Post-transaction, the reporting person retains beneficial ownership of 207,023 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were executed under a pre-established 10b5-1 plan, which is a routine administrative action for corporate insiders.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.
• The exercise of options demonstrates continued alignment with the company's long-term equity incentive structure.

Negatives

• The reporting person reduced their direct beneficial ownership stake in the company by 5,500 shares.

Risks

• Future share price volatility may impact the value of remaining equity holdings.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives in the biotechnology sector to manage personal liquidity and diversify holdings without signaling a lack of confidence in the company's clinical pipeline.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to avoid potential conflicts of interest regarding material non-public information.
• The volume of shares sold relative to the total holdings is consistent with typical executive compensation liquidation patterns.

Stakeholder Impact

• Shareholders should note the reduction in insider ownership, though it is mitigated by the use of a pre-planned trading arrangement.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, Stock Options, Biotech